ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1383	National Cancer Institute	Html	en	Primary CNS Lymphoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of primary CNS lymphoma.	neurologic toxic effects 0.298255 phase II study 0.301181 Median survival times 0.290496 autologous stem-cell transplantation 0.303999 intraocular lymphoma 0.357403 Int J Radiat 0.280843 multicenter trial 0.337891 high-dose chemotherapy 0.457349 Radiat Oncol Biol 0.35284 newly diagnosed patients 0.281995 median overall survival 0.288155 median OS 0.305882 oncology group study 0.287293 Median progression-free survival 0.289876 patients 0.38833 hematopoietic stem-cell rescue 0.299776 intensive chemotherapy 0.334942 refractory CNS lymphoma 0.401669 recurrent primary CNS 0.355753 Enhanced Chemotherapy Delivery 0.290362 immunodeficiency syndrome-related lymphoma 0.3182 radiation therapy 0.416652 radiotherapy 0.304692 high-dose cytarabine 0.339318	Ferreri AJ 0.299732 et al. 0.375948 brief single-agent methotrexate 0.293099 Non-AIDS Primary CNS 0.32387 intrathecal methotrexate 0.298746 PUBMED Abstract 0.333438 median time-to-treatment failure 0.282021 primary cns lymphoma 0.672691 median follow-up 0.314518 intraventricular methotrexate 0.280851 autologous stem cell 0.35468 radiation therapy oncology 0.371114 Abstract 0.508209 Clin Oncol 0.757019 Oncol Biol Phys 0.354909 high-dose methotrexate-based chemotherapy 0.379055 primary brain lymphoma 0.340924 Lymphoma Group Phase 0.33918 high-dose methotrexate-based therapy 0.321219 nervous system lymphoma 0.614476 primary cns 0.932952 therapy oncology group 0.373019 DeAngelis LM 0.317758 high-dose methotrexate 0.643572	CLICK HERE
1652	National Cancer Institute	Html	en	PC-SPES (PDQ®)–Patient Version	Expert-reviewed information summary about the use of PC-SPES as a treatment for prostate cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	cancer treatment 0.437115 cancer prevention 0.282542 Complementary Therapies Editorial 0.411772 United States 0.349637 Drug Administration 0.423619 Cancer Information Specialist 0.306354 PC-SPES 0.776503 Cancer Information Service 0.45748 PDQ cancer information 0.587454 Cancer Complementary 0.346119 CAM therapies 0.322693 treatment clinical trials 0.274541 National Cancer Institute 0.691988 clinical trials 0.701375 alternative medicine 0.539683 PC-SPES lowers PSA 0.309751 U.S. Food 0.291013 conventional treatment 0.269047 health care 0.271323 cancer information summary 0.466619 alternative cancer therapies 0.329832 Federal Trade Commission 0.302224 National Institutes 0.284819 cancer cells 0.400978	clinical trial 0.31949 National Center 0.264606 prostate cancer cells 0.342551 CAM cancer research 0.300048 breast cancer prevention 0.277639 cancer patients 0.279371 Cancer Care page 0.279808 prostate specific antigen 0.386617 traditional Chinese medicine 0.370287 health 0.346702 NCI’s PDQ 0.273024 PDQ summary 0.278148 Integrative Health 0.265541 NCI PDQ cancer 0.391945 cancer information database 0.323738 prostate cancer 0.519752 effects 0.26747 prescription medicines 0.565306 alternative therapies 0.390035 cancer information summaries 0.324417 Therapies Editorial Board 0.356431 cancer 0.944963 prostate problems 0.265671	CLICK HERE
1705	National Cancer Institute	Html	en	Cancer Vaccines	A fact sheet discussing how cancer vaccines are used to harness the body’s immune system to protect against cancer-causing viruses and as immunotherapy to treat existing cancers.	vaccines target 0.540823 Anti-cancer vaccines 0.524975 abnormal cells 0.538771 antitumor immune response 0.513051 cancer vaccines 0.904526 specific immune responses 0.519605 traditional vaccines 0.550486 cancer cells 0.789704 allogeneic vaccines 0.526888 human papillomavirus vaccines 0.559079 multiple vaccines 0.540847 immune responses 0.691208 killer T cells 0.622141 M. Cancer vaccines 0.584037 cancer-associated antigens 0.612713 dendritic cells 0.519133 white blood cells 0.606559 immune response 0.721657 cancer treatment vaccine 0.564337 dendritic cell vaccines 0.544937 immune checkpoint 0.531831 clinical trials 0.608279 anticancer vaccines 0.541706 anticancer immune response 0.511669	tumor cells 0.510012 anticancer immune responses 0.598324 effective treatment vaccines 0.575167 normal cells 0.555313 metastatic prostate cancer 0.537182 cancer treatment vaccines 0.999587 anti-idiotype vaccines 0.527061 prostate cancer cells 0.562932 immune cells 0.566337 cancer preventive vaccines 0.728942 cancer antigens 0.523547 tumor cell vaccines 0.548556 Forni G. Vaccines 0.537061 cells 0.810385 cytotoxic t cells 0.520347 Clinical Cancer Research 0.524363 strong immune response 0.509393 et al 0.519859 immune system cells 0.584226 cancer preventive vaccine 0.510434 current vaccines 0.524179 therapeutic cancer vaccines 0.612595 natural immune response 0.518594	CLICK HERE
1713	National Cancer Institute	Html	en	Mammograms	A fact sheet that defines screening and diagnostic mammograms; discusses the benefits and potential harms of screening mammograms; and summarizes how findings, including breast density, are reported.	mammography facility 0.617711 randomized breast screening 0.57821 mammograms 0.675286 tomosynthesis mammography 0.551922 3-D mammography 0.578436 health care provider 0.558006 breast implants 0.579825 clinical breast exams 0.637306 low-cost screening mammogram 0.569796 FDA-certified mammography facilities 0.561341 breast cancers 0.551598 dense breasts 0.550925 mammography screening programs 0.6099 diagnostic mammography 0.569303 conventional mammography 0.61609 standard digital mammography 0.569915 diagnostic mammogram 0.562845 high breast density 0.542253 mammography screening 0.620292 breast tissue 0.554504 Breast Imaging Reporting 0.535488 local mammography facility 0.561875 Regular breast self-exam 0.536763 mammogram 0.686942	breast cancer screening. 0.555392 digital mammography 0.659536 breast size 0.53014 regular screening mammography 0.636566 Mammography Quality Standards 0.561193 diagnostic mammograms 0.537673 digital breast tomosynthesis 0.539944 breast pain 0.528266 False-positive mammogram results 0.54885 mammography facilities 0.595109 breast cancer screening 0.594468 mammography 0.783904 breast density 0.567834 breast cancer 0.951318 annual screening mammograms 0.562698 standard mammography 0.551771 2-D mammography 0.551301 high-quality screening mammograms 0.56602 Mammography Imaging Screening 0.608506 previous breast biopsies 0.545681 screening mammogram 0.619625 false-negative results 0.544234 mammography providers 0.542876	CLICK HERE
1807	National Cancer Institute	Html	es	Tratamiento de la leucemia linfoblástica aguda infantil (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la leucemia linfoblástica aguda infantil.	Natl Acad Sci 0.307376 Pediatric Oncology 0.305639 cuadro clínico 0.310887 accessed august 0.319526 Cancer Statistics Review 0.318661 Sin embargo 0.315253 American Cancer Society 0.312133 células t 0.309906 acute lymphoblastic leukaemia 0.410489 childhood acute lymphoblastic 0.499677 Nat Rev Cancer 0.306219 Declining childhood 0.306804 Estados Unidos 0.313559 Natl Cancer Inst 0.305713 Howlader N 0.306702 cord blood from 0.305809 Nat Genet 0.357137 Childhood Oncology Group 0.313596 Smith MA 0.306166 SEER Cancer Statistics 0.320166 Lancet Oncol 0.309044 compromiso testicular manifiesto 0.308702 gen mll 0.318674 influences childhood 0.306473 leucemia aguda 0.314027	reordenamientos mll 0.307367 Lymphoblastic Leukemia Based 0.308731 Proc Natl Acad 0.307623 leucemia linfoblástica aguda 0.338126 Noone AM 0.306815 Pediatr Blood Cancer 0.327193 acute lymphocytic leukemia 0.309611 childhood leukaemia 0.319593 Chessells JM 0.307957 National Cancer Institute 0.329181 Genes Chromosomes Cancer 0.305628 with down 0.333227 childhood leukemia 0.309509 Hosking FJ 0.306858 Acute leukaemia 0.30596 sistema nervioso central 0.310053 Dutch Childhood Oncology 0.31389 childhood b-cell 0.31228 Krapcho M 0.307706 acute lymphoblastic leukemia 0.986055 leucemia mieloide aguda 0.30545 Mullighan CG 0.306442 minimal residual disease 0.306428 células b 0.314985	CLICK HERE
1834	National Cancer Institute	Html	es	Tratamiento del cáncer de células renales (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de células renales.	vena cava 0.123516 renal carcinoma 0.159056 Compton CC 0.125724 renal-cell carcinoma 0.14068 pazopanib versus sunitinib 0.125846 Sin embargo 0.110933 único tratamiento 0.110403 advanced renal 0.148043 7th ed 0.125599 randomized phase 0.121201 pelvis renal 0.120181 Escudier B 0.130262 dekernion jb 0.116071 patients with advanced 0.115714 nefrectomía citorreductora 0.116589 determinados pacientes 0.124987 Kidney Cancer 0.108755 metastatic renal cell 0.258997 metastatic renal carcinoma 0.150259 meses vs 0.112102 nefrectomía contralateral 0.112298 with metastatic renal 0.190502 Urol Clin North 0.118145 patients with metastatic 0.181521 single-center experience with 0.110273	lymphokine-activated killer cells 0.109085 cell carcinoma with 0.117134 determinados pacientes sobrevivirán 0.111069 metastatic renal 0.292754 Cancer Staging Manual 0.154868 National Cancer Institute 0.108824 advanced or metastatic 0.109154 advanced renal-cell carcinoma 0.125408 vena renal 0.12378 New York 0.121032 renal cell cancer 0.159738 cell carcinoma invading 0.114504 Clin Oncol 0.183599 Clin North Am 0.116365 or metastatic renal 0.109426 with advanced renal 0.117403 Byrd DR 0.123857 metastatic renal-cell carcinoma 0.127732 Tomczak P 0.112446 renal cell carcinoma 0.996231 Renal Pelvis Cancer 0.111495 células renales 0.815564 compared with 0.113419 AJCC Cancer Staging 0.157448	CLICK HERE
1901	National Cancer Institute	Html	es	Tratamiento del glioma de tronco encefálico infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del glioma de tronco encefálico infantil.	siguientes procedimientos 0.461896 IRM periódicas 0.425856 posibles factores 0.428641 efectos secundarios meses 0.538429 encéfalo benignos 0.484108 pontino intrínseco difuso 0.901206 efectos tardíos 0.636065 PDQ Efectos tardíos 0.495055 National Cancer Institute 0.428512 sustancia llamada gadolinio 0.454314 siguientes riesgos 0.420658 llamada neurofibromatosis tipo 0.456821 Instituto Nacional 0.447041 cinasa braf 0.631095 presente sumario 0.527425 PDQ Tratamiento 0.518077	determinados cambios 0.420201 neurofibromatosis tipo 0.564203 nuevos tipos 0.430533 sistema nervioso central 0.564289 Physician Data Query 0.500648 proteína braf 0.427497 Aboutâ„¢ Brain Tumors 0.435067 tumor dipg 0.504754 siguientes enlaces 0.422666 encefálico infantil recién 0.732248 panel derecho 0.429689 cuidado paliativo 0.460842 siguientes sumarios 0.465406 largo tiempo 0.418821 siguientes trastornos 0.430211	CLICK HERE
3434	National Cancer Institute	Html	es	Té y prevención de cáncer	Hoja informativa que resume los resultados de estudios realizados sobre el té y la prevención del cáncer. Incluye información sobre los ingredientes del té y las consideraciones de seguridad sobre el consumo de esta bebida.	tea polyphenol levels 0.306381 Gynecological Cancer 0.306129 Zhang M 0.301852 té oolong 0.345261 lung cancer 0.322075 green tea extract 0.319452 case-control study 0.308604 British Journal 0.30281 Breast Cancer Research 0.324861 Human Nutrition 0.301844 verde activa enzimas 0.302661 Singapore Chinese Health 0.30349 tea polyphenol 0.33584 black tea consumption 0.317861 Inoue M 0.303594 green tea rapidly 0.307366 nested case-control study 0.302496 PubMed Abstract 0.999235 tea consumption 0.35794 Women’s Health Study 0.302821 green tea consumption 0.326657 International Journal 0.309091 Yang CS 0.303196 cohort study 0.312904 Chinese Health Study 0.305698	Hakim IA 0.303206 Drinking green 0.302093 té verdeConcentración 0.313111 Health Study 0.306628 dietary intake 0.301921 Ohsaki study 0.302059 Cancer Research 0.340725 Iwasaki M 0.30184 Shanghai Cohort Study 0.302687 prospective cohort study 0.306347 subsequent risk 0.303163 Clinical Nutrition 0.305674 breast cancer 0.401322 modestly reduces breast 0.302193 tea consumption with 0.307242 extract supplement 0.301849 Cancer Institute 0.306085 controlled study 0.301969 Clinical Cancer Research 0.312026 prospective study 0.303895 green tea polyphenols 0.325122 tea catechins after 0.306288 Netherlands Cohort Study 0.306092 té verde—500 mg 0.313535	CLICK HERE
3514	National Cancer Institute	Html	en	What Are Clinical Trials?	Information about the basics of cancer clinical trials.	new ways 0.630193 cancer cells 0.475957 lab 0.434305 current treatments 0.466814 life 0.434324 successful cancer treatments 0.521796 protocol 0.451986 myth 0.41589 past clinical trials 0.525022 clinical trials 0.959728 animals 0.41616 plan 0.415114 longer lives 0.47341 knowledge 0.414644 final step 0.483148 cancer care 0.469342 new treatment 0.469236 disease 0.417585 charge 0.415053	new treatments 0.461251 researchers 0.43553 NCI-Supported Clinical Trials 0.532591 future patients 0.47375 people 0.521173 long process 0.483044 quality 0.434346 doctor 0.432193 effects 0.4317 cancer clinical trials 0.54508 principal investigator 0.542203 doctors 0.435633 needs treatment 0.4739 stages 0.415306 cancer 0.611137 research studies 0.485202 information 0.432449 time 0.415923	CLICK HERE
15644	National Cancer Institute	Html	en	Grant Resources	Resources to help with the NCI and NIH grants and funding process.	common grants terms 0.636173 Grants Administration 0.485213 application receipt dates 0.392845 grants lifecycle 0.493875 advisory boards 0.274696 peer review process 0.434219 Grant PDF 0.319331 special initiatives 0.261878 Federal Register 0.286844 legal notices 0.272989 official daily publication 0.406084 general description 0.295596 broad overview 0.295794 final regulations 0.265095 nih grants 0.999484 White House Office 0.40002 Funding Language 0.367422 grant process 0.330736 government-wide compendium 0.296699 award schedules 0.255197 Scientific Review 0.263296	NIH grants processing 0.800737 NIH electronic Research 0.624902 free NCI publications 0.595046 federal agencies 0.408435 local governments 0.266683 grants management contacts 0.622121 NIH-funded research projects 0.396147 NCI extramural funding 0.747162 NCI Division 0.471899 Extramural Activities 0.341398 nonprofit institutions 0.268579 NCI Office 0.478785 open funding opportunities 0.500892 ) Commons 0.273665 official resource 0.262995 NIH Publications 0.474143 financial assistance programs 0.412746 federal programs 0.291934 on-going administration requirements 0.443665 publications patents 0.270405 Federal Domestic Assistance 0.437119	CLICK HERE